Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash & Equivalents (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Cash & Equivalents for 16 consecutive years, with $57.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 3.33% to $57.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $57.5 million, a 3.33% increase, with the full-year FY2025 number at $57.5 million, up 3.33% from a year prior.
  • Cash & Equivalents was $57.5 million for Q4 2025 at Anika Therapeutics, down from $58.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $97.2 million in Q2 2021 to a low of $53.2 million in Q2 2025.
  • A 5-year average of $74.4 million and a median of $69.7 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: soared 43.7% in 2021, then decreased 28.8% in 2023.
  • Anika Therapeutics' Cash & Equivalents stood at $94.4 million in 2021, then dropped by 8.54% to $86.3 million in 2022, then decreased by 20.37% to $68.7 million in 2023, then decreased by 19.07% to $55.6 million in 2024, then rose by 3.33% to $57.5 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Cash & Equivalents are $57.5 million (Q4 2025), $58.0 million (Q3 2025), and $53.2 million (Q2 2025).